Cost-effectiveness analysis of the empirical antifungal strategy in oncohaematological patients;Estudio coste-efectividad de la estrategia empírica antifúngica en pacientes oncohematológicos

Farmacia Hospitalaria

Volumn 32, Issue 1, 2008, Pages 7-17

  Roma Sanchez E ^a   Poveda Andres J L ^a   Garcia Pellicer J ^a   Salavert Lleti M ^b   Jarque Ramos, I ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Antifungal agents; Cost effectiveness; Empiric therapy; Immunocompromised host

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; VORICONAZOLE; ANTIFUNGAL AGENT; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DRUG EFFICACY; FEMALE; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MYCOSIS; SENSITIVITY ANALYSIS; COST BENEFIT ANALYSIS; ECONOMICS; EMPIRICAL RESEARCH; LEUKEMIA; MIDDLE AGED; PROSPECTIVE STUDY; RETROSPECTIVE STUDY;

ANTIFUNGAL AGENTS; COST-BENEFIT ANALYSIS; EMPIRICAL RESEARCH; FEMALE; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; MYCOSES; PROSPECTIVE STUDIES; PYRIMIDINES; RETROSPECTIVE STUDIES; TRIAZOLES;

EID: 54049113884     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-6343(08)72804-6     Document Type: Editorial

References (31)

1. Jarque I., Salavert M., Romá E., Gobernado M., Chiveli M.A., Ruano M., et al. Guía del Hospital Universitario La Fe para la profilaxis y el tratamiento de las infecciones fúngicas en los enfermos inmunodeprimidos o que requieren cuidados especiales. Rev Esp Quimioter 17 (2004) 357-389
2. Pagano L., Caira M., Candoni A., Massimo O., Fianchi L., Martino B., et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 91 (2006) 1068-1075
3. Sevilla Azzati E., Rodríguez Escobar I., Martínez Nieto C., Pedraza Cerón L., Herrero A., Gutiérrez Ramos R., et al. Estudio multicéntrico de utilización de antifúngicos en el paciente oncohematológico. Farm Hosp 22 (1998) 188-196
4. Díaz-Pedroche C., Salavert M., Aguado J.M., Jarque I., Lizasoain M., and Sanz M.A. Evaluación individualizada del riesgo de infecciones en el paciente oncohematológico. Rev Esp Quimioter 19 (2006) 117-129
5. Sociedad Española de Quimioterapia y Asociación Española de Hematología y Hemoterapia. Temas de consenso: Profilaxis y tratamiento de las infecciones fúngicas en el paciente oncohematológico. Rev Esp Quimioterap 15 (2002) 387-401
6. Chamilos G., Luna M., Lewis R.E., Bodey G.P., Chemaly R., Tarrand J.J., et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 91 (2006) 986-989
7. Jarque I., Andreu R., Salavert M., Gómez D., Pemán J., Gobernado M., et al. Valor de la detección del antígeno galactomanano de Aspergillus en el diagnóstico y seguimiento de la aspergilosis invasora en pacientes hematológicos. Rev Iberoam Micol 20 (2003) 116-118
8. Grau Cerrato S., Mateu-de Antonio J., Soto Álvarez J., Muñoz Jareño M.A., Salas Sánchez E., Marín-Casino M., et al. Evaluación económica del uso de voriconazol versus anfotericina B en el tratamiento de la aspergilosis invasiva. Farm Hosp 29 (2005) 5-10
9. Jansen J.P., Meis J.F., Blijlevens N.M., and Van't Wout J.W. Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands. Curr Med Res Opin 21 (2005) 1535-1546
10. Jansen J.P., Kern W.V., Cornely O.A., Karthaus M., Ruhnke M., Ullmann A.J., et al. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany. Val Health 9 (2006) 12-23
11. Jorgensen K.J., Gotzsche P.C., and Johansen H.K. Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev 25 (2006) CD004707
12. Wenzel R., Del Favero A., Kibbler C., Rogers T., Rotstein C., Mauskopf J., et al. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. J Antimicrob Chemother 55 (2005) 352-361
13. Wingard J.R., Wood C.A., Sullivan E., Berger M.L., Gerth W.C., and Mansley E.C. Caspofungin versus amphotericin B for candidemia: a pharmacoeconomic analysis. Clin Ther 27 (2005) 960-969
14. Carnero Gómez R. Coste-efectividad del tratamiento antifúngico con Ambisome (anfotericina B liposómica). Rev Esp Econ Salu 4 (2005) 172-177
15. Wingard J.R., White M.R., Anaissie E., Raffalli J., Goodman J., and Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 31 (2000) 1155-1163
16. Kuti J.L., Kotapati S., Williams P., Capitano B., Nightingale C.H., and Nicolau D.P. Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections. Pharmacoeconomics 22 (2004) 301-310
17. Ascioglu S., Rex J.H., De Pauw B., Bennett J.E., Bille J., Crokaert F., et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an International Consensus. Clin Infect Dis 34 (2002) 7-14
18. Quindós G, Pemán J. Estrategias terapéuticas. Modalidades de tratamiento de la aspergilosis invasora. En: Pontón J, editor. Guía de bolsillo Aspergilosis invasora. Rev Iberoam Micol. 2003. p. 80. Disponible en http://www.aspergilosis.reviberoammicol.com/
19. Denning D.W., Ribaud P., Milpied N., Caillot D., Herbrecht R., Thiel E., et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Cin Infect Dis 34 (2002) 563-571
20. Bates D.W., Su L., Yu D.T., Chertow G.M., Seger D.L., Gomes D.R., et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 32 (2001) 686-693
21. Cagnoni P.J., Walsh T.J., Prendergast M.M., Bodensteiner D., Hiemenz S., Greenberg R.A., et al. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 18 (2000) 2476-2483
22. Wingard J.R., Wood C.A., Sullivan E., Berger M.L., Gerth W.C., and Mansley E.C. Caspofungin versus amphotericin B for candidemia: a pharmacoeconomic analysis. Clin Ther 27 (2005) 960-969
23. Walsh T.J., Finberg R.W., Arndt C., Hiemenz J., Schwartz C., Bodensteiner D., et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340 (1999) 764-771
24. Walsh T.J., Pappas P., Winston D.J., Lazarus H.M., Petersen F., Raffalli J., et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346 (2002) 225-234
25. Girois S.B., Cahpuis F., Decullier E., and Revol B. Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Eur J Clin Microbiol Infect Dis 25 (2006) 138-149
26. Collins C.D., Stuntebeck E.R., DePestel D.D., and Stevenson J.G. Pharmacoeconomic analysis of liposomal amphotericin B versus voriconazole for empirical treatment of febrile neutropenia. Clin Drug Investig 27 (2007) 233-241
27. Flückiger U., Marchetti O., Bille J., Eggimann P., Zimmerli S., Imhof A., et al. Treatment options of invasive fungal infections in adults. Swiss Med Wkly 136 (2006) 447-463
28. Cisneros J.M., Espigado I., Rivero A., Lozano de León F., Parra J., Collado A.R., et al. Tratamiento antifúngico empírico en pacientes seleccionados con fiebre persistente y neutropenia. Enf Infecc Microbiol Clin 23 (2005) 609-614
29. Shehab N., DePestel D.D., Mackler E.R., Collins C.D., Welch K., and Erba H.P. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia. Pharmacotherapy 27 (2007) 970-979
30. Greenberg R.N., Cagnoni P.J., Prendergast M.M., and Tong K.B. Pharmacoeconomics of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of persistently febrile neutropenic patients. 40th ICAAC 40 (2000) Abstract 506
31. Bruynesteyn K., Gant V., McKenzie C., Pagliuca T., Poynton C., Kumar R.N., et al. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suscpected fungal infections in the UK. Eur J Haematol 78 (2007) 532-539